Risk of multiple sclerosis after optic neuritis in patients with normal baseline brain MRI by Marques, IB et al.
Journal of Clinical Neuroscience 21 (2014) 583–586Contents lists available at ScienceDirect
Journal of Clinical Neuroscience
journal homepage: www.elsevier .com/ locate/ jocnClinical StudyRisk of multiple sclerosis after optic neuritis in patients with normal
baseline brain MRI0967-5868/$ - see front matter  2013 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.jocn.2013.06.013
⇑ Corresponding author. Tel.: +351 2 3940 0448; fax: +351 2 3982 2637.
E-mail address: inesmbmarques@gmail.com (I.B. Marques).Inês Brás Marques a,⇑, Fernando Matias a, Eduardo Duarte Silva b, Luis Cunha a, Lívia Sousa a
aDepartment of Neurology, Coimbra University Hospital, Praceta Mota Pinto, Coimbra 3000-075, Portugal
bDepartment of Ophthalmology, Coimbra University Hospital, Portugala r t i c l e i n f o
Article history:
Received 23 August 2012
Accepted 8 June 2013
Keywords:
Clinically isolated syndrome
Demyelinating diseases
Multiple sclerosis
Optic neuritisa b s t r a c t
When assessing and managing a patient with optic neuritis (ON), the risk of future development of
multiple sclerosis (MS) is an important issue, as this can be the ﬁrst presentation of the disease. Although
the presence of lesions on baseline brain MRI is the strongest predictor of MS conversion, some patients
with normal imaging also develop MS. We aimed to estimate MS risk in patients with ON and a normal
baseline MRI and identify individuals with higher risk of conversion. We performed a retrospective study
including patients with idiopathic ON and normal baseline brain MRI who presented to our hospital over
an 8 year period. Of a total of 42 patients, 10 converted to MS: ﬁve during the ﬁrst follow-up year, seven
during the ﬁrst 2 years and all of the patients within the ﬁrst 5 years, with a 5 year MS conversion rate of
23.8%. MS conversion rates were signiﬁcantly higher in patients with history of previous symptoms
suggestive of demyelination (p = 0.002), cerebrospinal ﬂuid oligoclonal bands unmatched in serum
(p = 0.004) and incomplete visual acuity recovery (66/12) after 1 year (p = 0.002). Lower conversion rates
were found in patients with optic disc edema (p = 0.022). According to these results, a signiﬁcant propor-
tion of patients with idiopathic ON and a normal baseline brain MRI will develop MS, with a higher risk
during the ﬁrst 5 years. Therefore, in the presence of factors in favor of MS conversion, close follow-up,
including semestral medical consultations and yearly brain MRI, can be recommended. Early immuno-
modulatory treatment may be individually considered as it can delay conversion and reduce new lesion
development rate.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Optic neuritis (ON) is the ﬁrst presentation of multiple sclerosis
(MS) in approximately 20% of patients [1,2] and the estimated risk
of MS conversion after ON is 30% at 5 years, 38% at 10 years and
50% at 15 years [3]. Therefore, when assessing and managing a
patient with isolated ON without an identiﬁable etiology, the
possibility of future development of MS has to be considered.
Determining which patients have a higher risk of conversion to
MS is important, as studies suggest that there may be a beneﬁt
from early immunomodulatory treatment in patients with
clinically isolated syndrome (CIS), including ON [4–10]. Although
the presence of one or more lesions on baseline brain MRI has been
identiﬁed as the strongest predictor of MS conversion [3,11–16],
there are patients with normal baseline MRI who also develop
MS and predictors of conversion are still to be determined in this
subgroup of patients.We aimed to estimate the risk of developing MS and identify
subjects with higher risk of conversion in a population of patients
with idiopathic ON and normal baseline MRI.
2. Methods
We performed a retrospective study of patients with idiopathic
ON and normal baseline MRI presenting to Coimbra University
Hospital, Portugal, between 2003 and 2010. Patients were found
by a search for ‘‘Optic Neuritis’’ (International Classiﬁcation of Dis-
eases, Ninth Revision, Clinical Modiﬁcation code 377.3) through
the hospital database. Clinical charts of all patients were reviewed
and demographic, clinical, paraclinical and treatment data were
systematically collected.
The diagnosis of ON was based on clinical criteria, including
subacute visual acuity loss, ocular pain exacerbated by eye
movements, dyschromatopsia and relative afferent pupillary
defect. Detection of conversion to clinically deﬁnite MS was based
on the occurrence of another clinical event suggestive of demyelin-
ating disease, excluding ON recurrence, during follow-up. MS diag-
nosis was performed according to the McDonald criteria approved
at the time of the diagnosis.
124
ON Diagnosis 
65
Idiopathic ON
29
Other Disease 
23
Baseline 
MRI with 
lesions 
42
Normal 
Baseline 
MRI 
15  
Autoimmune 
Disease 
8
Infectious 
Disease 
4
NMO 
2
Sarcoidosis 
30
MS
Fig. 1. Distribution of patients according to optic neuritis etiology. MS = multiple sclerosis, NMO = neuromyelitis optica, ON = optic neuritis.
Table 1
Distribution of patients according to visual acuity values at optic neuritis (ON)
diagnosis and after 1 year of follow-up
Visual acuity after 1 year of follow-up
6/60 6/18 6/15 6/12 6/7.5 6/6
Visual acuity at ON
diagnosis
<1/60 1 - - - - 2
1/60 1 - - - - 3
2/60 - - - - - 1
6/60 - 2 1 - - 3
6/30 - 1 3 - - -
6/18 - - - 1 1 -
6/15 - - - 1 - 3
6/12 - - - - 1 2
6/10 - - - - 7 2
6/7.5 - - - - - 6
584 I.B. Marques et al. / Journal of Clinical Neuroscience 21 (2014) 583–586Exclusion criteria included ON attributable to a disease other
than MS, previous diagnosis of MS and the presence of lesions on
baseline brain MRI.
All patients were evaluated by a neurologist and an ophthal-
mologist and a detailed clinical history, ophthalmologic examina-
tion and complete neurological examination was performed at
the time of the ﬁrst examination in our hospital. Visual acuity test-
ing was performed using the Snellen chart and expressed as a frac-
tion using the metric system. Reversal pattern visual evoked
potentials (VEP) and cerebrospinal ﬂuid analysis (CSF), including
oligoclonal band (OB) testing using isoelectric focusing with
immunoglobulin G immunoblotting, were performed during the
ﬁrst week after symptom onset in the majority of patients. In
VEP evaluation, P100 wave latency was considered prolonged
when it was higher than 115 milliseconds and P100 wave ampli-
tude was considered reduced when less than 50% of the value of
the contralateral eye. Gadolinium-enhanced 1.5 Tesla MRI (5 mm
slices with a 2.5 mm gap) was performed within the ﬁrst month
after ON onset in all patients.
Statistical analysis was performed using the Statistical Package
for the Social Sciences (SPSS Inc., Chicago, IL, USA). Continuous
variables were expressed as the mean with standard deviation
(SD), or medians. Categorical variables were expressed as absolute
and relative frequencies (percentages). The independent sample
t-test was used for comparison of means, Pearson’s chi-squared
test was used for comparing proportions and a logistic regression
model was used to test for the independent signiﬁcance of variables
signiﬁcant in the univariate analysis. All reported p values were two-
sided and considered statistically signiﬁcant if less than 0.05.3. Results
A total of 124 patients with a diagnosis of ON were identiﬁed in
the hospital database (Fig. 1). Thirty patients were excluded from
the study because of previous MS diagnosis and 29 patients were
excluded as they were ultimately diagnosed with another disease.
Among the 65 patients with idiopathic ON, 23 were excluded be-
cause of the presence of lesions suggestive of demyelinating dis-
ease in baseline brain MRI. Therefore, a total of 42 patients with
idiopathic ON and normal baseline MRI were identiﬁed.
The majority of patients were female (78.6%) and Caucasian
(100%) with a mean age at ON onset of 29.6 years (SD: 8.4 years,
range: 14–54 years). The mean follow-up time was 5.3 years (SD:
2.3 years). ON was unilateral in 88% of patients and retrobulbar
in 71.4%. Visual acuity was reduced in all patients, ranging from
only light perception to 6/7.5, and all patients had a central or par-
acentral visual ﬁeld defect. Neurological examination revealed
28.6% of patients had abnormalities not related to ON, including
hyperreﬂexia in 10 patients, nystagmus in three patients and mildataxia in one patient. Thirty-one percent of patients reported a his-
tory of previous symptoms suggestive of demyelination, including
previous episodes of sensory symptoms (paresthesia and/or hypo-
esthesia) in 11 patients and a remote episode of imbalance of a few
weeks duration with spontaneous recovery in two patients. VEP
were performed in 85.7% of patients with 29 patients with pro-
longed latency of the P100 wave and seven patients with pro-
longed latency and decreased amplitude of the P100 wave. CSF
analysis was performed in 95.2% of patients, with 12 patients with
more than two CSF OB unmatched in serum. Baseline brain MRI
had evidence of optic nerve involvement in 76% of the patients,
including optic nerve sheath gadolinium-enhancement (71%) and
optic nerve sheath dilatation (43%). Treatment with high-dose
intravenous methylprednisolone (1 g/day) was given to 83% of
patients over 3 to 7 days. Recovery after 1 year of follow-up was
evaluated based on visual acuity re-evaluation with 52.4% achiev-
ing total recovery (returning to visual acuity levels previous to ON),
and 47.6% achieving incomplete visual acuity recovery with
improvement equal or inferior to 6/12 (Table 1).
ON recurrence occurred in 31% of patients, including eight
patients with one recurrence and ﬁve patients with multiple
(two to six) recurrences.
A total of 10 patients developed clinical conversion to MS, ﬁve
during the ﬁrst year after ON, two during the second year, one
during the third year and two during the ﬁfth year of follow-up.
The mean time to MS diagnosis was 2.2 years (SD: 1.6 years,
median: 1.5 years) and the 5 year conversion rate was 23.8%. MS
conversion rate within 5 years of ON diagnosis was calculated for
the variables collected (Table 2).
A statistically signiﬁcant increase in MS conversion rate was
associated with a history of previous symptoms suggestive of
demyelination, OB in CSF unmatched in serum and incomplete
visual recovery after 1 year. Patients presenting with optic disc
Table 2
Multiple sclerosis conversion rates according to demographic, clinical, paraclinical and treatment variables
Patient characteristics Patients, n MS conversion rate (%) p value Odds ratio 95% CI
Sex Female 33 24.2 0.9 - -
Male 9 22.2
ON Unilateral 37 21.6 0.365 - -
Bilateral 5 40
Fundoscopy Disc edema 12 0 0.022 0.67 0.51–0.86
Retrobulbar ON 30 33.3
Other abnormalities on NE Yes 12 33.3 0.359 - -
No 30 20
Previous symptoms suggestive of demyelination Yes 13 53.8 0.002 10.1 2–51
No 29 10.3
Oligoclonal bands in CSF Positive 12 58.3 0.001 11.7 2.2–61.3
Absent 28 10.7
Treatment IV methylprednisolone 35 25.7 0.517 - -
No treatment 7 14.3
Visual acuity recovery after 1 year Incomplete 20 45 0.002 17.2 1.9–153.7
Complete 22 4.5
Recurrence Yes 13 30.8 0.478 - -
No 29 20.7
CSF = cerebrospinal ﬂuid, IV = intravenous, MS = multiple sclerosis, NE = neurological examination, ON = optic neuritis.
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signiﬁcant differences in MS conversion rate were found related to
patient sex, ON laterality, the presence of other neurological exam-
ination abnormalities, corticosteroid treatment, or ON recurrence.
Among patients who ultimately converted to MS, the abnormal-
ities detected in the neurological examination were mild ataxia
and hyperreﬂexia, and the reported previous symptoms suggestive
of demyelination were imbalance and sensory symptoms. All
patients with MS conversion had P100 wave prolonged latency
and in three patients P100 wave amplitude was also diminished.
Visual acuity recovery was incomplete in all but one of the patients
who developed MS. Four patients with ON recurrence (one to two
recurrences) converted to MS.
Although patients with MS conversion were slightly older at ON
diagnosis (32.9 ± 7.4 years) than patients without conversion
(28.63 ± 8.5 years), this difference was not statistically signiﬁcant
(p = 0.163).4. Discussion
This study emphasizes that a signiﬁcant proportion of patients
presenting with isolated ON and a normal baseline brain MRI will
develop MS, especially in the ﬁrst follow-up years. We found a
23.8% 5 year risk of developing MS, a value in accordance with pre-
vious reports, which estimate MS conversion rates between 10%
and 30% in these patients [3–9]. The Optic Neuritis Treatment Trial
[3], the largest study on MS risk after ON, included 191 patients
with ON without baseline brain MRI lesions, with a conversion risk
in this subgroup of 16% at 5 years, 22% at 10 years and 25% at
15 years, suggesting higher risk of MS development in the ﬁrst
5 years and very low probability of conversion after 10 years of fol-
low-up. In our study, we also found a higher MS conversion rate
during the ﬁrst years after ON, with 70% of conversions occurring
during the ﬁrst 3 years and 100% during the ﬁrst 5 years.
We identiﬁed a higher MS conversion rate in patients with pre-
vious history of symptoms suggestive of demyelination, a feature
estimated to be present in one-third of the patients presenting
with a ﬁrst demyelinating event and increasingly being considered
to be useful in predicting conversion to MS [17,18].
The Poser criteria for MS diagnosis [19], used between 1983 and
2001, considered OB a laboratory support for MS diagnosis, but the
diagnosis of laboratory supported deﬁnite MS in patients with OB
implied the presence of other clinical or paraclinical evidence. In
the subsequent 2001, 2005 and 2010 McDonald Diagnostic Criteriafor Relapsing Remitting MS [20–22], MRI assumed a preponderant
value in MS diagnosis, and the presence of OB was no longer con-
sidered in the diagnostic criteria. Nevertheless, in clinical practice,
the presence of OB in CSF continues to be a factor in favor of MS
diagnosis in the appropriate clinical context and a useful tool for
predicting the prognosis of patients presenting with CIS. Higher
MS conversion rates in patients who have OB in CSF has also been
reported in other studies, with an estimated two-fold increase in
MS risk in patients with OB, independent of the presence of lesions
in the MRI [23].
None of the patients with baseline optic disc edema developed
MS, reinforcing the idea that this feature may be associated with a
lower risk of developing MS, as already reported in the Optic
Neuritis Treatment Trial [3]. In patients with MS, ON is classically
retrobulbar in the majority of patients [3,24], which is explained by
the fact that the intraocular optic nerve is composed of unmyeli-
nated axons and the optic nerve myelin sheath only begins after
the retinal ganglion cell axons pass through the lamina cribrosa,
surrounding only the retrobulbar portion of the optic nerve [25].
Although mild diffuse optic disc edema can be seen in one-third
of patients with demyelinating lesions because of transudation of
ﬂuids from injured axons and disc vessels, optic disc edema is more
common and obvious when there is blockage of orthograde axo-
plasmic ﬂow by mechanical or ischemic processes [25]. For this
reason, the presence of optic disc edema is less suggestive of future
development of MS than retrobulbar ON.
In patients with MS, axonal loss is reported in the early stages of
the disease, including CIS, and is associated with irreversible dam-
age and incomplete recovery [26–29]. Studies with optic coherence
tomography have demonstrated axonal loss in the retinal nerve
ﬁber layer in patients with MS in the early stages of the disease
[30–32]. This early axonal loss is probably the reason why most
of our patients with subsequent MS conversion had incomplete
recovery after the ﬁrst clinical presentation of the disease. There-
fore, we believe that incomplete recovery must be regarded as a
warning signal of increased risk for MS conversion.
Contrary to other studies [3,7,33,34], we did not ﬁnd an associ-
ation between MS risk and sex, age or ON recurrence.
This study suggests that previous symptoms suggestive of
demyelination, OB in CSF unmatched in serum, incomplete visual
acuity recovery and retrobulbar ON are factors predicting MS
conversion. When these factors are present, close follow-up,
including semestral medical consultations and yearly brain MRI,
can be recommended, at least during the ﬁrst 5 years. Early
586 I.B. Marques et al. / Journal of Clinical Neuroscience 21 (2014) 583–586immunomodulatory treatment may be considered as it can prevent
or delay conversion, reduce the development of new subclinical
lesions and improve the clinical outcome [4–10]. Treatment
decision must be individualized and reserved for high risk patients,
as some patients will never develop MS.
There are some limitations that need to be acknowledged and
addressed regarding the present study, including the small size
of the sample and retrospective nature. We also recognize that
the population of patients with ON is possibly underrepresented
as various factors may affect patient selection, including coding
errors in the hospital database and the fact that some patients
never present for medical evaluation, especially when there is
spontaneous recovery. MS conversion rate may also have been
underestimated as only clinical MS conversion was considered
and new silent subclinical lesions, that would allow MS diagnosis
according to the current MS diagnosis criteria [22], may have been
missed.
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